Logo image of BNR

BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Fundamental Analysis

NASDAQ:BNR - Nasdaq - US12233L2060 - ADR - Currency: USD

7.15  +0.06 (+0.85%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BNR. BNR was compared to 572 industry peers in the Biotechnology industry. BNR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BNR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BNR has reported negative net income.
In the past year BNR has reported a negative cash flow from operations.
BNR had negative earnings in each of the past 5 years.
BNR had a negative operating cash flow in each of the past 5 years.
BNR Yearly Net Income VS EBIT VS OCF VS FCFBNR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -200M -400M -600M -800M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.41%, BNR is in line with its industry, outperforming 51.87% of the companies in the same industry.
With a Return On Equity value of -65.96%, BNR perfoms like the industry average, outperforming 57.37% of the companies in the same industry.
Industry RankSector Rank
ROA -43.41%
ROE -65.96%
ROIC N/A
ROA(3y)-53%
ROA(5y)-43.23%
ROE(3y)-70.7%
ROE(5y)-56.83%
ROIC(3y)N/A
ROIC(5y)N/A
BNR Yearly ROA, ROE, ROICBNR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

BNR has a better Gross Margin (68.72%) than 82.42% of its industry peers.
BNR's Gross Margin has been stable in the last couple of years.
BNR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.55%
GM growth 5Y0.89%
BNR Yearly Profit, Operating, Gross MarginsBNR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNR has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for BNR has been increased compared to 5 years ago.
BNR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNR Yearly Shares OutstandingBNR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
BNR Yearly Total Debt VS Total AssetsBNR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of -5.23, we must say that BNR is in the distress zone and has some risk of bankruptcy.
BNR has a worse Altman-Z score (-5.23) than 63.06% of its industry peers.
There is no outstanding debt for BNR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.23
ROIC/WACCN/A
WACC7.92%
BNR Yearly LT Debt VS Equity VS FCFBNR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 1B 2B

2.3 Liquidity

A Current Ratio of 3.04 indicates that BNR has no problem at all paying its short term obligations.
With a Current ratio value of 3.04, BNR is not doing good in the industry: 65.19% of the companies in the same industry are doing better.
A Quick Ratio of 2.78 indicates that BNR has no problem at all paying its short term obligations.
BNR has a worse Quick ratio (2.78) than 66.07% of its industry peers.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.78
BNR Yearly Current Assets VS Current LiabilitesBNR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

BNR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.34%, which is quite impressive.
The Revenue has decreased by -8.54% in the past year.
Measured over the past years, BNR shows a very strong growth in Revenue. The Revenue has been growing by 20.81% on average per year.
EPS 1Y (TTM)73.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y7.73%
Revenue growth 5Y20.81%
Sales Q2Q%0.85%

3.2 Future

The Earnings Per Share is expected to grow by 35.32% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.93% on average over the next years. This is quite good.
EPS Next Y95.52%
EPS Next 2Y35.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20.21%
Revenue Next 2Y33.54%
Revenue Next 3Y18.66%
Revenue Next 5Y16.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BNR Yearly Revenue VS EstimatesBNR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
BNR Yearly EPS VS EstimatesBNR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BNR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNR Price Earnings VS Forward Price EarningsBNR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNR Per share dataBNR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

BNR's earnings are expected to grow with 35.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.32%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BNR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURNING ROCK BIOTECH LTD-ADR

NASDAQ:BNR (2/21/2025, 8:03:58 PM)

7.15

+0.06 (+0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2024-08-29/amc
Earnings (Next)N/A N/A
Inst Owners42.4%
Inst Owner Change-63.89%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap73.35M
Analysts80
Price TargetN/A
Short Float %0.84%
Short Ratio5.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.04
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-25.56
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS6.86
BVpS8.71
TBVpS8.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.41%
ROE -65.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.72%
FCFM N/A
ROA(3y)-53%
ROA(5y)-43.23%
ROE(3y)-70.7%
ROE(5y)-56.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.55%
GM growth 5Y0.89%
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.78
Altman-Z -5.23
F-Score4
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)171.57%
Cap/Depr(5y)179.87%
Cap/Sales(3y)19.06%
Cap/Sales(5y)17.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.98%
EPS Next Y95.52%
EPS Next 2Y35.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y7.73%
Revenue growth 5Y20.81%
Sales Q2Q%0.85%
Revenue Next Year20.21%
Revenue Next 2Y33.54%
Revenue Next 3Y18.66%
Revenue Next 5Y16.93%
EBIT growth 1Y38.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.61%
OCF growth 3YN/A
OCF growth 5YN/A